ZYBERNO
Stock Report
Updated Sep 1, 2026

Femasys Inc. (FEMY)

Healthcare • NASDAQ

$3.38

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
19.0/100
POOR BUSINESS
Femasys Inc. (FEMY) scores 19/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-216.5%)
Debt-to-Equity (Solvency Risk):GOOD (0.49x)
Operating Margin (Operational Efficiency):CRITICAL (-763.9%)
Return on Capital (Capital Efficiency):CRITICAL (-341.6%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Femasys Inc. (FEMY) stock report — Zyberno Score 19/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, FEMY generated -$18.41M in Owner Earnings. Capital was deployed as follows: $161.76K returned via share buybacks, $507.54K invested in capital expenditures. Reinvestment rate: -1.4%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:3.38
Market Cap:$11.35M

Valuation Multiples (3)

P/B Ratio:2.81x
P/S Ratio:4.93x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$11.17M

Price Action & Momentum (3)

Momentum Percentile:2 / 100
% of 52-Week High:15.2%
B. Profitability Assessment

Return Metrics (5)

ROA:-71.5%
Reinvestment Rate:-1.4%
Fundamental Growth Rate (g):4.7%

Margin Analysis (3)

Operating Margin Ttm:-763.9%
Net Margin Ttm:-511.8%
Ebitda Margin:-747.6%

TTM Performance (3)

Gross Margin Ttm:60.9%
Operating Margin Ttm:-763.9%
Net Margin Ttm:-511.8%

Yield Metrics (2)

Earnings Yield:-$78.60
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-990.2%
Latest Earnings Filed:2026-08-14

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):22.8%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:2.14x
Quick Ratio:0.55x
Cash Ratio:0.37x

Leverage Analysis (3)

Debt To Equity Ttm:0.49x
Debt-to-Equity Ratio:0.49x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-13.50x
Times Interest Earned:-13.50

Capital Structure (4)

Working Capital:4,445,087.00
Cash And Cash Equivalents:1,443,502.00
Long Term Debt:$795.99K
Net Debt:-$174.48K
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $2.30M
Linear Growth: 22.8%
📊 Click to view full FEMY Revenue analysis & methodology →
Cost Of Revenue Ttm:$898.01K

Profitability Breakdown (2)

Gross profit TTM: $1.40M
Linear Growth: 20.8%
📊 Click to view full FEMY Gross Profit analysis & methodology →
-$17.57M

Bottom Line Performance (3)

-$11.77M
Income Before Tax:-$11.76M
Ebitda Ttm:-17,191,970.00

Operating Expenses (5)

Operating Expenses:18,967,395.00
R And D Expense:6,451,082.00
Sga Expense:7,020,320.00
Income Tax Expense:$6.35K
Interest Expense:1,302,827.00

Expense Ratios (3)

R And D To Revenue Percentage:1,944.1%
Sga To Revenue Percentage:2,115.7%
Ebitda Margin:-747.6%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$12.29M
Current Assets:$8.33M
Ppe Net:5,791,530.00
Goodwill:0.00
Intangible Assets:$115.50K

Liability Structure (4)

Total Liabilities:8,258,635.00
Current Liabilities:3,886,826.00
Long Term Debt:$795.99K
Short Term Debt:$473.03K

Equity & Capital (3)

Equity:$4.03M
Retained Earnings:-$149.45M
Common Stock:200,000,000.00

Working Capital Items (3)

Accounts Receivable:151,049.00
Inventory:6,191,277.00
Accounts Payable:2,337,354.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:210,820.00
C. Cash Flow Analysis

Operating Activities (2)

-$18.07M-$18.58M

Investment Activities (2)

Investing Cash Flow:-$79.14K
Capital Expenditures Ttm:507,540.00

Financing Activities (3)

Financing Cash Flow:$342.33K
Dividends Paid Ttm:0.00
Stock Repurchase:161,761.00

Capital Transactions (3)

Common Stock Issuance:7,998,826.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:373,933.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-1.80
-$1.80
Earnings Per Share Ttm:-$3.51

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.68
Operating Cash Flow Per Share:-$5.57

Book Value & Capital (2)

Book Value Per Share:$1.20
Cash Per Share:0.43

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.14x
Working Capital Turnover Ttm:0.52x

Receivables Management (2)

Receivables Turnover Ttm:15.22x
Days Sales Outstanding Ttm:23.98

Inventory Management (2)

Inventory Turnover Ttm:0.15x
Days Inventory Outstanding Ttm:2,516.48

Payables & Cash Cycle (2)

Days Payable Outstanding:950.03
Cash Conversion Cycle:1,590.43
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$18.41M

Damodaran Growth Analysis (2)

Reinvestment Rate:-1.4%
Fundamental Growth Rate (g):4.7%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):22.8%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):20.8%
Book Value Growth Rate (Linear):-37.7%
C. Company Profile & Context

Corporate Information (6)

Symbol:FEMY
Company Name:Femasys Inc.
Sector:Healthcare
Industry:Medical Devices
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:3.36M
Shares Outstanding Basic:3.36M
Shares Outstanding Diluted:3.36M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 13:34:50 UTC
Data Timestamp:2026-08-21T09:18:32.293094
Scroll to Top